Longevity Drugs: What the New Nature Aging Paper Really Shows

Longevity drugs are moving from biohacker chatter into serious geroscience, but the gap between a molecular map and a prescription is still wide. The new Nature Aging paper by Bnaya Gross, Joseph Ehlert, Vadim Gladyshev, Joseph Loscalzo and Albert-László Barabási matters because it organizes thousands of genes, hallmarks of aging and existing drugs into a network. It does not matter because it found a pill that makes humans live longer.

The search query "longevity drugs" tends to split into two weak answers: enthusiastic lists of anti-aging molecules, or blanket rejection of any pharmacological intervention. Neither is clinical thinking. The useful reading is more precise: some medicines may modulate aging mechanisms, but we still need cell validation, animal work where appropriate, human trials, long-term safety and clear selection criteria.

At Progevita, this paper matters because it fits the logic behind personalized longevity protocols: measure before intervening, separate hypotheses from clinical evidence, and never confuse a molecular mechanism with a medical indication.

Clinical and editorial review: July 2026. This analysis was prepared with a YMYL lens, prioritizing the original paper, peer-reviewed biomedical sources, safety guidance and the criteria of the Progevita medical team under the direction of Dr Miguel Ángel Fernández Torán.

Why this paper matters

Aging is not one pathway. It is a network of interacting processes: chronic inflammation, cellular senescence, mitochondrial dysfunction, epigenetic change, intercellular communication, nutrient sensing, dysbiosis and more. The hallmarks of aging are useful because they organize the field, but they can mislead if we read them as independent switches.

The Barabási team starts from network medicine: diseases and biological phenotypes are not usually driven by one gene, but by connected protein modules. If the genes linked to a hallmark occupy a defined neighborhood in the interactome, researchers can ask which drugs have targets close to that neighborhood. Proximity does not prove benefit, but it helps prioritize hypotheses.

The valuable addition is that the study does not stop at "this drug touches this network". It adds SHARP, the systematic hallmark-based aging repurposing pipeline, and within that pipeline uses pAGE, a gene-expression metric. If some genes rise or fall with age, pAGE asks whether a drug pushes that signature in the opposite direction or in the same direction. In plain English: it is not enough to perturb a module; direction matters.

What the researchers actually did

Step	What they did	Why it matters
Longevity genes	They started with 2,358 OpenGenes entries linked to longevity, age-related disease or aging pathways.	This avoids building the analysis around a few famous genes.
Hallmarks	They assigned 1,250 genes to 11 hallmarks; 390 were linked to more than one hallmark.	Inflammation, metabolism, senescence and repair are not separate boxes.
Interactome	They mapped those genes onto 524,156 validated interactions among 18,223 proteins.	This allows proximity between drug targets and aging modules to be measured.
Drugs	They evaluated 6,442 approved or experimental compounds from DrugBank.	Repurposing starts from medicines with existing target and safety information.
SHARP + pAGE	They combined network proximity with drug-induced expression signatures compared with age-associated expression shifts.	This helps separate potentially favorable candidates from compounds that may reinforce aging signatures.

The clinically interesting point is not the list of names. It is the method: network proximity plus direction of effect. That reduces a common longevity mistake, where people say "this pathway is involved in aging, therefore targeting it must be good". In biology, pushing a pathway without knowing direction, dose, tissue and context can backfire.

SHARP: why proximity to a hallmark is not enough

Network proximity answers a limited question: whether a medicine's targets sit near an aging module. SHARP adds a second question: whether the medicine's transcriptional signature appears to move against the aging pattern or with it. That second layer prevents a drug from being labeled "longevity" just because it touches a famous pathway.

Filter	Paper result	Careful clinical reading
Compounds evaluated	6,442 approved or clinically tested DrugBank compounds.	The starting library is broad, but still built from known targets.
Hallmark proximity	370 drugs showed significant proximity to at least one hallmark.	Proximity means "may perturb", not "benefits".
CMap data	60 of the 370 had enough expression profiles to calculate pAGE.	310 candidates remain incomplete until better transcriptional data exist.
Positive pAGE	21 compounds showed a favorable signal across all analyzed confidence levels.	These are candidates for experimental validation, not preventive treatments.
Negative pAGE	23 compounds showed potentially age-accelerating signals.	The same network that suggests opportunity can also detect caution.

This detail changes the headline. The paper does not say "there are 370 longevity drugs"; it says 370 drugs are close to aging modules, only 60 had enough expression data, and 21 deserve special experimental attention because pAGE was positive. That is less viral, but far more useful.

Computational is not clinical

This point is essential. A computational study can be very useful without being enough to change medical practice. The paper describes falsifiable predictions. That means they need to be tested: first in appropriate cell systems, then in animals when relevant, and later in humans with meaningful outcomes.

Several questions sit behind every headline:

• Dose: a drug may have a favorable signature at one experimental dose and adverse effects at another.
• Tissue: a signal in a cell line is not the same as an effect in brain, muscle, arteries or immune cells. The paper notes its reliance on MCF7/CMap profiles because of data coverage.
• Duration: modulating a pathway for days is different from taking a medicine for years.
• Profile: a person with diabetes, inflammation or high cardiovascular risk is not the same as a healthy 35-year-old.
• Hormesis: some stress responses that rise with age may be adaptive in specific contexts; not every "pro-age" signature is automatically harmful.
• Outcome: changing gene expression is not the same as fewer heart attacks, less frailty, better memory or more independent years.

The right takeaway is not "Nature Aging found longevity drugs". It is: Nature Aging proposed a more disciplined way to prioritize medicines that could be tested against aging mechanisms.

Aspirin, oxymetazoline and the easy headline

Some examples attract attention because they are familiar. Northeastern's coverage mentions aspirin as having a signal related to intercellular communication and nutrient sensing, and oxymetazoline, found in nasal decongestant sprays, as an unexpected candidate for altered intercellular communication. This is exactly where readers need restraint.

When a known drug appears in a network analysis, that does not mean it should be used for longevity. Aspirin can increase bleeding risk; the USPSTF recommends individualizing initiation in adults aged 40 to 59 with elevated cardiovascular risk and recommends against starting it for primary prevention in adults aged 60 or older. Oxymetazoline can cause rebound congestion and cardiovascular effects when misused. Metformin, rapamycin, senolytics, anti-inflammatory drugs and metabolic drugs each have their own indications, risks and uncertainties.

The clinical question is not "which drug appeared in the paper". It is "which patient, with which risk profile, what goal, which biomarker, which safer alternative and what stopping rule".

What this changes for metformin, rapamycin and senolytics

Metformin already had biological plausibility in longevity through AMPK, glucose metabolism, inflammation and nutrient sensing. But our review of metformin and longevity reaches the same cautious conclusion this paper supports: mechanism is not an indication in healthy people. It may make medical sense in insulin resistance or prediabetes; its anti-aging benefit in metabolically healthy people is not proven.

Rapamycin and rapalogs may be the strongest examples of pharmacological geroscience in animals. The Interventions Testing Program showed lifespan extension in mice, even when treatment began late. In humans, low-dose mTOR inhibitors have shown interesting immune signals in older adults, but that does not make rapamycin a harmless biohack. Dose, immunity, lipids, glucose, infection risk, wound healing and interactions matter.

Senolytics are another promising field: clearing senescent cells makes biological sense and has strong preclinical data. But moving from mice to people requires indication-specific trials, not DIY stacks because "zombie cells" sounds persuasive. Our article on senolytics explains that caution in more detail.

Class	Human evidence today	Main risk	When it belongs in a clinical conversation
Metformin	Extensive diabetes data and observational studies; TAME is designed to test delayed chronic disease, not immortality.	Low B12, gastrointestinal effects, renal adjustment, possible interaction with exercise adaptation in some contexts.	Insulin resistance, prediabetes, diabetes or a specific cardiometabolic profile.
Rapamycin / rapalogs	Strong animal signal; small human immune trials and recent healthy-adult studies with preliminary signals.	Immunity, lipids, glucose, wound healing, infections, interactions; evidence remains insufficient for broad preventive use.	Only with a clinician monitoring dose, labs, adverse effects and a measurable goal.
Senolytics	Strong preclinical biology and human trials for specific indications; general healthspan use in healthy adults is unproven.	Toxicity, platelet suppression depending on compound, interactions and poor patient selection.	Clinical research or specific indications, not DIY stacks.
Aspirin	Useful in selected cardiovascular contexts; primary prevention has become more restrictive.	Gastrointestinal or intracranial bleeding, especially with age, NSAIDs, anticoagulants or hypertension.	Individual cardiovascular risk, not "for longevity".
GLP-1 drugs	Strong evidence in diabetes, obesity and cardiometabolic events in indicated profiles; indirect interest through inflammation and risk.	Lean-mass loss without protein and strength training, gastrointestinal effects, cost and rebound without a transition plan.	Obesity, diabetes, fatty liver or cardiometabolic risk, with a muscle-preserving plan.
Acarbose	Interesting Interventions Testing Program signal and metabolic clinical use; limited use as a human longevity intervention.	Gas, diarrhea, poor adherence and narrow indication.	Postprandial glucose control and metabolic profile, not an anti-aging shortcut.

The clinical matrix forces a more adult question than "what can I take?". The question is: is there a real indication in my case, or am I trying to turn a geroscience hypothesis into a prescription?

The clinical map before discussing drugs

When someone comes to a clinic asking about longevity drugs, the responsible order does not start with a candidate list. It starts with a clinical map.

Clinical question	What to measure first	Why it changes the conversation
Is cardiometabolic risk present?	ApoB, LDL-C, Lp(a), blood pressure, HbA1c, insulin, triglycerides, waist.	If risk is high, proven interventions come before anti-aging hypotheses.
Is inflammation persistent?	hsCRP, suPAR when appropriate, ferritin, symptoms, sleep, oral health, visceral fat.	Inflammation may have treatable causes that do not require experimental drugs.
Is functional reserve low?	VO2 max, grip strength, chair-stand test, muscle mass, balance.	No drug compensates for frailty, low strength or inactivity.
What medication is already in use?	Full medication and supplement list, alcohol, kidney/liver function, B12, interactions.	Real risk often lies in combinations, not one molecule in isolation.
What outcome is the goal?	Pain, glucose, lipids, sleep, physical capacity, symptoms, quality of life.	Without a measurable goal, there is no way to know if a protocol helps.

This is the bridge between geroscience and preventive medicine. Drugs may have a role, but only after measurement. Sometimes measurement shows that the best "longevity drug" for a given person is lowering ApoB, treating sleep apnea, gaining muscle or reducing alcohol.

How we interpret this at Progevita

At Progevita, we do not treat longevity as a molecule list. We treat it as a problem of diagnosis, priorities and follow-up. In programmes such as Optimization and Inflammaging, longevity biomarkers, physical function, sleep, inflammation, body composition and medical history drive the strategy.

A paper like this helps us ask better questions: which hallmark is most active, which pathway deserves monitoring, which drug deserves a trial, which marker could show response. But it does not change the clinical rule: no medication belongs in a longevity plan without an indication, informed consent, contraindication review, monitoring and a stopping rule.

Responsible longevity medicine is not anti-drug. It is anti-shortcut.

What to do if you want to explore longevity drugs

• Do not start by buying. Start by knowing which problem you are trying to solve.
• Map real risk. Cardiometabolic, inflammatory, functional, sleep, current medication and family history.
• Prioritize what already reduces events. Blood pressure, ApoB, glucose, strength, VO2 max, sleep and tobacco matter more than most molecular hypotheses.
• Ask for stopping rules. If no one knows when to stop an intervention, it is probably not well designed.
• Repeat relevant measurements. A protocol without follow-up is a bet, not preventive medicine.

Conclusion

The new Nature Aging paper is serious because it changes the way longevity drugs can be discussed: less intuition, more network biology; fewer isolated names, more mechanism; less blind enthusiasm, more testable hypotheses.

For patients, the translation is cautious. There is currently no approved drug to slow aging in healthy adults. There are useful medicines for specific diseases, promising candidates, ongoing trials and a better map of the hallmarks. Between that map and a prescription sits medicine.

The question is not whether longevity drugs will exist one day. The practical 2026 question is: what data from your body justify discussing them today, and which stronger-evidence interventions have not yet been optimized?

Frequently asked questions about longevity drugs

Does the Nature Aging paper prove that existing drugs extend human lifespan?

No. It proposes candidates using network biology and gene-expression signatures. It is a research prioritization map, not clinical proof that any drug extends human life.

What does drug repurposing mean in longevity medicine?

It means studying known medicines for new uses related to aging mechanisms. Existing safety data can speed research, but controlled trials are still needed.

Should I take aspirin, metformin or rapamycin for longevity?

No, not on your own. These drugs have indications, contraindications and interactions. Responsible longevity medicine weighs clinical profile, risk, biomarkers and monitoring.

What is pAGE?

pAGE is the SHARP metric that estimates whether drug-induced gene-expression changes oppose or reinforce expression shifts associated with aging. A favorable value creates a hypothesis, not a medical indication.

What should a patient do with this information?

Use it to ask better questions, not to buy drugs. Start with cardiometabolic risk, physical function, inflammation, sleep, current medication and measurable goals.

References

1. Gross B, Ehlert J, Gladyshev VN, Loscalzo J, Barabási AL. "Network-driven discovery of repurposable drugs targeting hallmarks of aging." Nature Aging. 2026. DOI: 10.1038/s43587-026-01161-8.
2. Nature Aging. "Mapping the network architecture of aging to identify repurposable drug candidates for longevity." Nature Aging. 2026. DOI: 10.1038/s43587-026-01160-9.
3. Guarente L, Sinclair DA, Kroemer G. "Human trials exploring anti-aging medicines." Cell Metabolism. 2024;36:354-376. PMID: 38181790.
4. Espinoza SE, et al. "Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease: Proceedings of a National Institute on Aging Workshop." Journals of Gerontology: Series A. 2023;78(Suppl 1):53-60. PMID: 37325957.
5. Hands JM, Lustgarten MS, Frame LA, Rosen B. "What is the clinical evidence to support off-label rapamycin therapy in healthy adults?" Aging. 2025;17:2079-2088. DOI: 10.18632/aging.206300.
6. Moel M, Harinath G, Lee V, et al. "Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results." Aging. 2025;17:908-936. DOI: 10.18632/aging.206235.
7. American Federation for Aging Research. "TAME - Targeting Aging with Metformin." AFAR.
8. U.S. Preventive Services Task Force. "Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication." 2022. USPSTF.
9. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. "Hallmarks of aging: an expanding universe." Cell. 2023;186:243-278. PMID: 36599349.
10. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. "The Hallmarks of Aging." Cell. 2013;153:1194-1217. PMID: 23746838.
11. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. "Metformin as a Tool to Target Aging." Cell Metabolism. 2016;23:1060-1065. PMID: 27304507.
12. Harrison DE, Strong R, Sharp ZD, et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature. 2009;460:392-395. PMID: 19587680.
13. Mannick JB, Del Giudice G, Lattanzi M, et al. "mTOR inhibition improves immune function in the elderly." Science Translational Medicine. 2014;6:268ra179. PMID: 25540326.
14. Kirkland JL, Tchkonia T. "Cellular Senescence: A Translational Perspective." EBioMedicine. 2017;21:21-28. PMID: 28416161.
15. Northeastern Global News. "Study finds existing drugs could be repurposed for longevity by tapping network of aging-related genes." 2026. Northeastern.

This content is educational and does not replace individual medical care. Do not start, stop or combine drugs for longevity without medical supervision.